An analysis of redactions in Canada’s Common Drug Review Clinical Review Reports and how they relate to the patients’ voice

IMPORTANCE: Canada’s Common Drug Review (CDR) evaluates drug data from published and unpublished research, as well as input from patient groups, to recommend provincial coverage. Currently, the CDR process gives manufacturers the opportunity to redact information in the final publicly available repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Soprovich, Allison, El Kurdi, Sylvia, Eurich, Dean T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595205/
https://www.ncbi.nlm.nih.gov/pubmed/28893743
http://dx.doi.org/10.1136/bmjopen-2016-015497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595205/
https://www.ncbi.nlm.nih.gov/pubmed/28893743
http://dx.doi.org/10.1136/bmjopen-2016-015497

Ejemplares similares